Mr James Frith

Mr James Frith

Labour — Bury North

Speaking in the House of Commons on 17 November 2026

Debate

Medicines and Healthcare Products Regulatory Agency

Contribution

I will make some progress before I take interventions shortly. The issues we have discussed matter enormously. Medicines and medical devices affect us all, often when we are at our most vulnerable. The public must be able to trust the system that regulates those medicines and devices. It must be rigorous, independent and transparent and, when concerns are raised, they must be heard. I acknowledge that the experiences of patients and families that hon. Members have raised remain deeply difficult. Good regulation requires us not simply to explain the system but to listen carefully when people raise concerns and issues. I keep in mind Bev in my constituency of Bury, who lives daily with the effects of pelvic mesh and the complete destruction of her physical relationship, which she wanted me to convey. I think of Janet and Emma, also from Bury, and their incredible sodium valproate campaign, and all the testimony we have heard today. Regulation needs to occur regularly, not as a one-off event. It needs to be in a permanent state of review, as does the review of the regulator itself. The MHRA has a critical responsibility; its fundamental purpose is to protect the public by ensuring that medicines and devices meet appropriate standards of safety, quality, performance and effectiveness. It must do that independently, based on the best available evidence. Regarding independence, as referred to by the right hon. Member for East Antrim (Sammy Wilson), fees are payable regardless of the outcome of an application, and are designed to recover the cost of providing the regulatory service, rather than generate a profit. Though subject to scrutiny and the need to be robust, that model is the right one, consistent with global regulators. The hon. Member for Strangford (Jim Shannon) asked about my contact with Northern Ireland. I have two dates in January and February to visit Northern Ireland, in my first few months in this role. I am happy to pre-meet him for a discussion and will be sure to pick up the issue with counterparts in Northern Ireland. Some hon. Members asked whether reporting by healthcare professionals should be mandatory. Manufacturers already have statutory reporting obligations, while professional guidance provides for healthcare professionals to act on safety concerns. There is currently limited evidence that making it mandatory for healthcare professionals to report would improve the ability to detect signs of possible safety problems. I am conscious that that sounds like a denial or dismissal, but my assessment of the model is that what we actually need is much more access to patients and that patients need access to the system. At the moment, it is effectively a business-to-business or organisation-to-organisation model, and the patient is not in the loop. One of my responsibilities in health innovation, around the new iterations of the NHS app and the development of NHS Digital, is to ensure verified information, so as to lance the disinformation about the efficacy of vaccines the hon. Member for Christchurch (Sir Christopher Chope) mentioned. Patients need to be able to speak to the system more effectively. The NHS app development I am overseeing is beginning to have that thought; I spoke this morning to the MHRA about leaning more into that. That should not be interpreted as complacency about under-reporting. The MHRA is improving connections between yellow card and clinical systems, working with healthcare partners to increase reporting, making it easier to use, and developing its capability to use data and analytics to identify emerging risks earlier. I will say more on the yellow card system later. I note that there has been a significant improvement in the MHRA’s operational performance in the past 18 months, thanks to Government funding and appropriate resource. A question was posed about whether there is enough resource and funding. When 99% of national medicines licence applications were determined on time and 97% of clinical trials and investigations assessed within target, I believe the answer is yes. Lord O’Shaughnessy agrees: his independent review highlighting the significant challenges facing the clinical trials environment described the MHRA’s progress on performance since then as “remarkable”. On the matter of clinical trials, we have just confirmed the movement from 153 days to 100 days for launching clinical trials, with an appetite to go further and faster. That is an important point in answer to the issues raised about accessing clinical trials, freedom to engage with clinical trials and the pathway to market for the drugs and trial successes in question. I commit to writing to the Opposition spokesperson, the hon. Member for Sleaford and North Hykeham (Dr Johnson), about the issue of vaccine damage payments. On the matter of puberty blockers that she raised, I recognise her concerns, and hon. Members have rightly highlighted the role of the MHRA in strengthening safeguards. However, I remind hon. Members that a judicial review concluded in July 2026 and the High Court rejected challenges to the regulatory decisions made in the assessment of the pathways trial, stating that: “The MHRA is responsible for the safety of the clinical trial and the safeguarding of participants. It undertook a rigorous process to assess the trial before giving its initial approval in…2025.” Crucially, that performance extends to safety monitoring, with the MHRA continuing to exceed its targets for processing serious adverse incident reports within 24 hours. That shows it is a fast and responsive regulator that can collaborate with the wider system and take action to protect patients when potential risks are identified.

More from Mr James Frith

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Mr James Frith's full parliamentary record including voting history, expenses and all other contributions, see the Mr James Frith report card.